We demonstrate that psoriasis coexists with a state of vascular inflammation that is compatible with an increased risk of cardiovascular events. Treatment with anti-TNFα and anti-IL-17 drugs prevents leukocyte recruitment by the endothelium and protects against the onset of thrombosis, effects that are not attributable to anti-IL-12/23. These results endorse the appropriateness of earlier initiation of treatment of psoriatic patients at a high risk of developing CV with selected biologics.
- A researcher in training position is offered
- The 2nd International Workshop on Liver and Gut Fibrosis will take place in Valencia, Spain, on 26-27 October 2023.
- CONFERENCE: ADVANCES IN COMPLICATED IN IBD. 17 February 2023, in Fundación-ADEIT
- Research stay in Dublin
- Our article published recently in the British Journal of Pharmacology
abacavir acif antiretrovirals autophagy cerebral-vascular damage cGKI chronic liver disease ciberehd colon Crohn's disease designations doctoral prize doctoral studies efavirenz excellence research group fibroblast fibrosis fibrostat fpi fpu gut hiv hospital de manises hospital universitario dr. peset hospital universitario y politécnico la fe incorporations inflammatory bowel disease liver liver injury macrophages master degree mitophagy newspapers and journals p2x7 pharmacology prometeo programme psoriasis rilpivirina sucnr1 technician thrombosis tytgat institute for liver and intestinal research university of zurich vascular reactivity vitamin d